Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARS1 | P26639 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21274225 | 1.00 | TARS1 (0.37) | TARS1ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL30379388 | 0.95 | ADORA3 (0.37) | ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL2033389 | 0.90 | ADORA1 (0.38) | TARS1ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL30037173 | 0.90 | ADORA1 (0.38) | TARS1ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL17371759 | 0.88 | TARS1 (0.37) | TARS1SLC29A1ADORA1 | |
| SCHEMBL27641587 | 0.85 | SLC29A1 (0.38) | ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL29089525 | 0.83 | TARS1 (0.39) | TARS1SLC29A1ADORA1 | |
| SCHEMBL16987222 | 0.81 | TARS1 (0.38) | TARS1SLC29A1ADORA1 | |
| SCHEMBL28564130 | 0.81 | TARS1 (0.38) | TARS1SLC29A1ADORA1 | |
| SCHEMBL29435121 | 0.81 | TARS1 (0.38) | TARS1SLC29A1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577243-A1 | STABLE LIPID OR LIPIDOID NANOPARTICLE SUSPENSIONS | Ethris GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| EP-4536825-A2 | SYSTEMS FOR ENHANCING TARGET MRNA EXPRESSION AND USES THEREOF | The Johns Hopkins University (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025045767-A1 | STABILIZED LIPID AND LIPIDOID NANOPARTICLE FORMULATIONS WITH SPECIFIC SURFACTANT PROPERTIES FOR ENHANCED PHARMACEUTICAL APPLICATIONS | ETHRIS GMBH (DE) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025038850-A1 | LIPID NANOPARTICLES AND METHODS FOR SENSITIZING RESPONSE TO AN IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2023240254-A9 | SYSTEMS FOR ENHANCING TARGET MRNA EXPRESSION AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024042236-A1 | STABLE LIPID OR LIPIDOID NANOPARTICLE SUSPENSIONS | ETHRIS GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023240254-A2 | SYSTEMS FOR ENHANCING TARGET MRNA EXPRESSION AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-12-14 | — | — | WO | disclosed |